- Record: found
- Abstract: found
- Article: not found
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Jessica L Mega
1 ,
Tabassome Simon ,
Jean-Philippe Collet ,
Jeffrey L Anderson ,
Elliott M Antman ,
Kevin Bliden ,
Christopher P Cannon ,
Nicolas Danchin ,
Betti Giusti ,
Paul Gurbel ,
Benjamin D Horne ,
Jean-Sebastian Hulot ,
Adnan Kastrati ,
Gilles Montalescot ,
Franz-Josef Neumann ,
Lei Shen ,
Dirk Sibbing ,
P Gabriel Steg ,
Dietmar Trenk ,
Stephen D Wiviott ,
Marc S Sabatine
Oct 27 2010
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Clopidogrel, one of the most commonly prescribed medications, is a prodrug requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes.